When cancer is diagnosed, finding treatment options is the top priority
OncoTarget® Series is our comprehensive genomic profiling solution to identify targeted immunotherapies for advanced cancers– solid tumors or leukemias.
Learn about our newly launched, FDA cleared, 500-gene panel - OncoTarget® 500*
OncoTarget® Series Test Menu
FDA cleared gene panel testing
- Cleared for all solid tumors
- 100% clinical biomarkers covered
- Includes: CDx, NCCN guideline-directed targeted genes
- Cost-effective
- Timely
Coming soon
An NGS-Based Test For Myeloid Leukemia
- NGS-bases gene panel (68 genes)
- High density coverage of sequencing reads
- Targets known mutations associated with acute myeloid leukemia (AML), MPN, MDS, CML and JMML
AML Prognostics:
- FLT3
- NPM1
- CEBPA
- TP53
- BCR-ABL1 Mbcr (p210) Quantitative Analysis for Minimal Residual Disease (MRD)
- 68 Genes Targeted Whole Exon Sequencing
- JAK2 V617F:
- If Neg, Reflex to JAK2 Exon 12
- If Neg, Reflex to MPL
- If Neg, Reflex to CALR
- CALR
- JAK2 Exon 12
- MPL
- PDGFRA
- TET2
- T-CELL Gene Rearrangement
- B-CELL Gene Rearrangement
Acute Lymphocytic Leukemia (ALL) panel:
Acute Myelogenous (AML) panel:
Chronic Lymphocytic (CLL) panel:
Chronic Myelogenous (CML) probe:
Myelodysplastic (MDS) panel:
Multiple Myeloma (MM) panel:
- t(1;19) PBX1/TCF3
- t(9;22) BCR/ABL1
- 11q23 KMT2A (MLL) rearrangements
- t(12;21) ETV6(TEL)/RUNX1(AML)
- trisomy 4, 5, 10, 17
Acute Myelogenous (AML) panel:
- inv(3), t(3;3) RPN1/MECOM rearrangements
- del(5q) EGR1
- del(7q)/monosomy 7
- t(8;21) RUNX1T1(ETO)/RUNX1(AML)
- 11q23 KMT2A (MLL) rearrangements
- t(15;17) PML/RARA
- inv(16), t(16;16) CBFB rearrangements
Chronic Lymphocytic (CLL) panel:
- del(11q) ATM/del(17p) TP53
- trisomy 12/del(13q) 13q14/13q34
- t(11;14) CCND1/IGH XT
Chronic Myelogenous (CML) probe:
- t(9;22) BCR/ABL1
Myelodysplastic (MDS) panel:
- inv(3), t(3;3) RPN1/MECOM rearrangements
- del(5q) EGR1
- del(7q)/monosomy 7
- trisomy 8/del(20q)
- 11q23 KMT2A (MLL) rearrangements
- del(13q) 13q14/13q34
Multiple Myeloma (MM) panel:
- 1p32.3/1q21 CDKN2C/CKS1B
- t(11;14) CCND1/IGH XT
- del(13q) 13q14/13q34
- del(17p) TP53
- reflex:
- t(4;14) FGFR3/IGH
- t(14;16) IGH/MAF
- del(5q) EGR1
- del(7q)/monosomy 7
- trisomy 8/del(20q)
- t(9;22) BCR/ABL1
- 11q23 KMT2A MLL rearrangements
- 4q12 FIP1L1/CHIC2/PDGFRA
- 5q33 PDGFRB rearrangements
- 8p11 FGFR1 rearrangements
- 2p23 ALK (Anaplastic) rearrangements
- 3q27 BCL6 rearrangements (Diffuse Large B-cell, Follicular, Marginal Zone B-cell)
- 8q24 MYC rearrangements
- t(11;14) CCND1/IGH XT (Mantle Cell)
- 18q21 BCL2 rearrangements
- reflex:
- t(8;14) MYC/IGH (Burkitt or Follicular)
- t(11;18) BIRC3/MALT1
- t(14;18) IGH/BCL2
- 2p23 ALK (Anaplastic) rearrangements
- 14q11.2 TRA rearrangements
- 7q34 TRB rearrangements
- i(7q) 7cen/7q22/7q31
- 14q32 TCL1A
- 10q24 TLX1
- 5q35 TLX3
- PDL-1
- MSI
- MMR
Your confidence is found within OncoTarget’s
multi-technology platform
multi-technology platform
MSI and Single Mutations
FISH
next-generation sequencing
Immunohistochemistry
#ASCO22 week is here and we are excited to announce the release of our FDA-Cleared CGP Test under OncoTarget® 500.
Visit us in booth #28109 on June 4-6 between 9:00 AM–5:00 PM each day and learn how this CGP solution will help advance cancer treatments by identifying genomic targets for both targeted therapy and immunotherapy.
Visit us in booth #28109 on June 4-6 between 9:00 AM–5:00 PM each day and learn how this CGP solution will help advance cancer treatments by identifying genomic targets for both targeted therapy and immunotherapy.